Physician
Mile Bluff Medical Center INC
Mile Bluff Medical Center INC was paid $6.56M by Medicaid between Jan 2018 and Dec 2024, across 218 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 7.4% of everything it billed.
33Billing provider infoMILE BLUFF MEDICAL CENTER INC
MAUSTON, WI 53948
MAUSTON, WI 53948
33aNPI1568487411assigned 07/13/2006
33bProvider typeEmergency Medicine Physician
28Total paid$6.56M
24GClaims337,611
24DCodes billed218
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in Wisconsin
Rank by total paid#3 of 230
Median peer was paid$7K
This provider vs. median912×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 42,194 | $1.04M | |
| 2019 | 45,661 | $1.01M | |
| 2020 | 46,357 | $1.05M | |
| 2021 | 53,344 | $1.08M | |
| 2022 | 51,356 | $834K | |
| 2023 | 52,825 | $817K | |
| 2024incomplete | 45,874 | $730K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 7.4% | 4,790 | 4,238 | $484K |
| 80053 | Comprehensive metabolic panel | 6.7% | 17,717 | 14,715 | $437K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.6% | 9,464 | 8,135 | $366K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.4% | 5,308 | 4,789 | $287K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.9% | 4,163 | 2,254 | $257K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3.5% | 4,568 | 4,199 | $230K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.5% | 2,372 | 1,642 | $227K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.3% | 4,826 | 2,490 | $217K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.9% | 6,796 | 5,815 | $188K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.8% | 4,105 | 3,629 | $184K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.7% | 20,836 | 16,856 | $176K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.6% | 2,408 | 2,219 | $173K |
206 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.2% | 1,331 | $144K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.2% | 2,132 | $141K |
| 99214 | Doctor's office visit, returning patient (more involved) | 2.1% | 2,208 | $138K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.0% | 7,285 | $130K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.8% | 2,990 | $120K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.8% | 1,755 | $118K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 2,219 | $118K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 1,829 | $113K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 1,766 | $104K |
| 83880 | 1.6% | 2,936 | $102K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.5% | 2,979 | $98K |
| 80061 | Lipid panel | 1.5% | 4,855 | $95K |
| 82805 | 1.2% | 3,624 | $80K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 1,500 | $77K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.1% | 5,246 | $72K |
| 87480 | 1.1% | 2,308 | $72K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 5,073 | $71K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.1% | 1,952 | $70K |
| 85610 | <1% | 3,924 | $64K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,638 | $62K |
| 81001 | <1% | 9,910 | $61K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,931 | $60K |
| 99284 | Emergency room visit (serious) | <1% | 1,540 | $59K |
| 84145 | <1% | 3,237 | $49K | |
| 99000 | <1% | 398 | $49K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 634 | $46K |
| 87510 | <1% | 2,331 | $45K | |
| 87660 | <1% | 2,308 | $43K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,679 | $39K |
| 87077 | <1% | 2,859 | $38K | |
| 81025 | <1% | 2,219 | $34K | |
| 83605 | <1% | 4,743 | $34K | |
| 87070 | <1% | 1,051 | $28K | |
| 80306 | <1% | 1,251 | $27K | |
| 86140 | <1% | 4,827 | $27K | |
| 73630 | <1% | 1,589 | $25K | |
| 84484 | <1% | 4,392 | $24K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 777 | $23K |
| 85027 | <1% | 3,681 | $21K | |
| 87634 | <1% | 416 | $21K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 300 | $20K |
| 84439 | <1% | 1,368 | $19K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 414 | $18K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 220 | $17K |
| 84703 | <1% | 1,445 | $17K | |
| 82728 | <1% | 1,063 | $16K | |
| 83690 | <1% | 3,249 | $16K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 225 | $15K |
| 85007 | <1% | 1,694 | $15K | |
| 82948 | <1% | 1,598 | $14K | |
| 83735 | <1% | 3,396 | $14K | |
| 87186 | <1% | 2,055 | $13K | |
| 73030 | <1% | 997 | $13K | |
| 85379 | <1% | 1,951 | $12K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,267 | $12K |
| 73562 | <1% | 830 | $11K | |
| 82607 | <1% | 852 | $11K | |
| 86703 | <1% | 259 | $11K | |
| 84702 | <1% | 388 | $11K | |
| 86618 | <1% | 681 | $11K | |
| 73610 | <1% | 798 | $10K | |
| 83655 | <1% | 247 | $10K | |
| 87040 | <1% | 1,545 | $10K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 453 | $9K |
| 59025 | Fetal non-stress test | <1% | 147 | $9K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 157 | $9K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 197 | $9K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 148 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 37,929 | $8K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,548 | $7K |
| 82077 | <1% | 887 | $7K | |
| 72100 | <1% | 443 | $7K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 60 | $7K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 425 | $6K |
| 82043 | <1% | 830 | $6K | |
| 84481 | <1% | 490 | $6K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 694 | $6K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,174 | $6K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 101 | $6K |
| 88142 | <1% | 299 | $5K | |
| 73502 | <1% | 443 | $5K | |
| 73560 | <1% | 363 | $5K | |
| 76830 | Ultrasound, transvaginal | <1% | 84 | $5K |
| 80320 | <1% | 620 | $5K | |
| 73110 | <1% | 372 | $5K | |
| 85652 | <1% | 2,302 | $5K | |
| 84460 | <1% | 977 | $5K | |
| 83540 | <1% | 773 | $4K | |
| 80329 | <1% | 321 | $4K | |
| 87507 | <1% | 12 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 24 | $4K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,455 | $4K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 94 | $4K |
| 71250 | <1% | 194 | $4K | |
| 73130 | <1% | 250 | $4K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 104 | $4K |
| 86803 | <1% | 297 | $4K | |
| 86780 | <1% | 361 | $4K | |
| 83550 | <1% | 499 | $3K | |
| 87340 | <1% | 363 | $3K | |
| G0378 | Hospital observation service, per hour | <1% | 492 | $3K |
| 84100 | <1% | 1,059 | $3K | |
| 82565 | <1% | 286 | $3K | |
| 85730 | <1% | 556 | $3K | |
| 80055 | <1% | 41 | $3K | |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 52 | $3K |
| 82746 | <1% | 116 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 77 | $2K |
| 93017 | <1% | 96 | $2K | |
| 76801 | <1% | 45 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 37 | $2K |
| 82274 | <1% | 52 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,812 | $2K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 180 | $2K |
| 86850 | <1% | 534 | $2K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 17 | $2K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 155 | $2K |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 54 | $2K |
| 81015 | <1% | 550 | $1K | |
| 82947 | <1% | 115 | $1K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 15 | $1K |
| 80076 | <1% | 47 | $1K | |
| 84450 | <1% | 284 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 287 | $1K |
| 82150 | <1% | 174 | $1K | |
| 76642 | <1% | 14 | $1K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 163 | $1K |
| 81003 | <1% | 269 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 27 | $984.02 |
| 86900 | <1% | 446 | $980.11 | |
| 99285 | Emergency room visit (most serious) | <1% | 19 | $979.97 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,810 | $874.08 |
| 86901 | <1% | 446 | $855.49 | |
| 0352U | <1% | 396 | $852.17 | |
| 93041 | <1% | 1,402 | $764.51 | |
| 84153 | <1% | 13 | $752.15 | |
| 82977 | <1% | 76 | $708.38 | |
| 82550 | <1% | 180 | $687.56 | |
| 92557 | <1% | 32 | $626.48 | |
| 73565 | <1% | 130 | $569.45 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 14 | $506.20 |
| 94660 | <1% | 13 | $487.32 | |
| 85014 | <1% | 102 | $472.67 | |
| 74019 | <1% | 109 | $447.85 | |
| 83615 | <1% | 141 | $391.56 | |
| 86762 | <1% | 34 | $386.62 | |
| 82247 | <1% | 24 | $334.84 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 15 | $310.38 |
| 85018 | <1% | 152 | $304.56 | |
| 80179 | <1% | 59 | $270.66 | |
| 82248 | <1% | 67 | $236.86 | |
| 80143 | <1% | 45 | $208.74 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 65 | $208.41 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,362 | $203.39 |
| 86704 | <1% | 15 | $151.81 | |
| 86038 | <1% | 14 | $150.78 | |
| 82784 | <1% | 15 | $145.78 | |
| 87205 | <1% | 55 | $141.51 | |
| 82330 | <1% | 13 | $141.38 | |
| 86706 | <1% | 15 | $135.35 | |
| 82375 | <1% | 20 | $127.30 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 24 | $105.13 |
| 82010 | <1% | 14 | $92.84 | |
| 72040 | <1% | 15 | $92.20 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,635 | $73.99 |
| 92567 | <1% | 13 | $63.45 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 563 | $62.26 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,848 | $54.68 |
| 84550 | <1% | 14 | $46.55 | |
| 96376 | <1% | 600 | $43.64 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,023 | $33.83 |
| 97162 | <1% | 43 | $24.00 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,017 | $22.21 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,134 | $19.43 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,302 | $16.55 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 768 | $7.13 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 24 | $5.88 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 948 | $4.74 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 124 | $3.30 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 685 | $3.23 |
| J3490 | Unclassified drugs | <1% | 345 | $2.56 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 844 | $1.85 |
| J7627 | Budesonide, inhalation solution, compounded product, administered through dme, unit dose form, up to 0.5 mg | <1% | 19 | $1.70 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 464 | $1.39 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 255 | $0.83 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 130 | $0.43 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 607 | $0.00 |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | 0% | 63 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 46 | $0.00 |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | 0% | 64 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 16 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 18 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 52 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 18 | $0.00 |
| 93000 | 0% | 19 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 92 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 138 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 49 | $0.00 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 32 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 28 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 80 | $0.00 |
| S0164 | Injection, pantoprazole sodium, 40 mg | 0% | 60 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 15 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 13 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 21 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKAMINSKI, THOMAS (VP/CFO)
| Provider | Location | Paid |
|---|---|---|
| Mile Bluff Medical Center INC | Mauston, WI | $1.55M |
| Mile Bluff Medical Center INC | New Lisbon, WI | $540K |
| Mile Bluff Medical Center INC | Wisconsin Dells, WI | $364K |
| Mile Bluff Medical Center INC | Mauston, WI | $311K |
| Mile Bluff Medical Center INC | Elroy, WI | $291K |
| Mile Bluff Medical Center INC | Necedah, WI | $229K |
| MBMC Mauston Phillips LLC | Mauston, WI | $148K |
| Mile Bluff Medical Center INC | Mauston, WI | $96K |
| Mile Bluff Medical Center INC | Mauston, WI | $10K |
| Mile Bluff Medical Center INC | Wisconsin Dells, WI | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.